Patent · US Active

Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells

US11976126B2 · kind B2 · utility

0Cited by

9References

24Claims

0Family size

Assignee

Inhibrx, Inc. · US

Inventors

John C. Timmer · Village of La Jolla, US
Kyle S. Jones · San Marcos, US
Amir S. Razai · Village of La Jolla, US
Abrahim Hussain · Village of La Jolla, US
Katelyn M. Willis · Village of La Jolla, US
Quinn Deveraux · Village of La Jolla, US
Brendan P. Eckelman · Village of La Jolla, US

Key dates

Filing date	Aug 5, 2021
Grant date	May 7, 2024
Priority date	—
Expiry date	Dec 1, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.